{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:29:02Z","timestamp":1784813342313,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,11,16]],"date-time":"2014-11-16T00:00:00Z","timestamp":1416096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s10549-014-3202-5","type":"journal-article","created":{"date-parts":[[2014,11,15]],"date-time":"2014-11-15T06:26:27Z","timestamp":1416032787000},"page":"591-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG)"],"prefix":"10.1007","volume":"148","author":[{"given":"Emmanouil","family":"Saloustros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Malamos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Boukovinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Kakolyris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Kouroussis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Athanasiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Ziras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kentepozidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisis","family":"Makrantonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristidis","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Christophyllakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Mavroudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,16]]},"reference":[{"key":"3202_CR1","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Radcliffe Infirmary CTSU","year":"2005","unstructured":"Radcliffe Infirmary CTSU (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"3202_CR2","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686\u20133696","journal-title":"J Clin Oncol"},{"key":"3202_CR3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.2003.02.063","volume":"21","author":"IC Henderson","year":"2003","unstructured":"Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ et al (2003) Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976\u2013983","journal-title":"J Clin Oncol"},{"key":"3202_CR4","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302\u20132313","journal-title":"N Engl J Med"},{"key":"3202_CR5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S1470-2045(12)70525-9","volume":"14","author":"JR Mackey","year":"2013","unstructured":"Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP et al (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14:72\u201380","journal-title":"Lancet Oncol"},{"key":"3202_CR6","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","volume":"24","author":"H Roche","year":"2006","unstructured":"Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664\u20135671","journal-title":"J Clin Oncol"},{"key":"3202_CR7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jnci\/djn151","volume":"100","author":"M Martin","year":"2008","unstructured":"Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L et al (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100:805\u2013814","journal-title":"J Natl Cancer Inst"},{"key":"3202_CR8","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa0909638","volume":"362","author":"SM Swain","year":"2010","unstructured":"Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER et al (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053\u20132065","journal-title":"N Engl J Med"},{"key":"3202_CR9","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1200\/JCO.2010.28.5437","volume":"29","author":"W Eiermann","year":"2011","unstructured":"Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M et al (2011) Phase III study of doxorubicin\/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29:3877\u20133884","journal-title":"J Clin Oncol"},{"key":"3202_CR10","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1200\/JCO.2012.48.1275","volume":"31","author":"SM Swain","year":"2013","unstructured":"Swain SM, Tang G, Geyer CE Jr, Rastogi P, Atkins JN et al (2013) Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol 31:3197\u20133204","journal-title":"J Clin Oncol"},{"key":"3202_CR11","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1517\/14656566.9.15.2603","volume":"9","author":"E Saloustros","year":"2008","unstructured":"Saloustros E, Mavroudis D, Georgoulias V (2008) Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother 9:2603\u20132616","journal-title":"Expert Opin Pharmacother"},{"key":"3202_CR12","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","volume":"23","author":"SE Jones","year":"2005","unstructured":"Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L et al (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542\u20135551","journal-title":"J Clin Oncol"},{"key":"3202_CR13","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"AD Seidman","year":"2008","unstructured":"Seidman AD, Berry D, Cirrincione C, Harris L, Muss H et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 non overexpressors: final results of cancer and leukemia group B protocol 9840. J Clin Oncol 26:1642\u20131649","journal-title":"J Clin Oncol"},{"key":"3202_CR14","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA, Wang M, Martino S, Jones V, Perez EA et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663\u20131671","journal-title":"N Engl J Med"},{"key":"3202_CR15","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/jnci\/djq409","volume":"102","author":"L Bonilla","year":"2010","unstructured":"Bonilla L, Ben-Aharon I, Vidal L, Gafter-Gvili A, Leibovici L et al (2010) Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102:1845\u20131854","journal-title":"J Natl Cancer Inst"},{"key":"3202_CR16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/annonc\/mdl355","volume":"18","author":"P Piedbois","year":"2007","unstructured":"Piedbois P, Serin D, Priou F, Laplaige P, Greget S et al (2007) Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin\/cyclophosphamide (T\/EC), or the reverse sequence (EC\/T), every 2\u00a0weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3\u00a0weeks. AERO B03 randomized phase II study. Ann Oncol 18:52\u201357","journal-title":"Ann Oncol"},{"key":"3202_CR17","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S1470-2045(05)70424-1","volume":"6","author":"M Trudeau","year":"2005","unstructured":"Trudeau M, Charbonneau F, Gelmon K, Laing K, Latreille J et al (2005) Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 6:886\u2013898","journal-title":"Lancet Oncol"},{"key":"3202_CR18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10549-009-0468-0","volume":"119","author":"A Polyzos","year":"2010","unstructured":"Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N et al (2010) FEC versus sequential docetaxel followed by epirubicin\/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Res Treat 119:95\u2013104","journal-title":"Breast Cancer Res Treat"},{"key":"3202_CR19","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741\/cancer and leukemia group B trial 9741. J Clin Oncol 21:1431\u20131439","journal-title":"J Clin Oncol"},{"key":"3202_CR20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bjc.6604862","volume":"100","author":"RL Jones","year":"2009","unstructured":"Jones RL, Walsh G, Ashley S, Chua S, Agarwal R et al (2009) A randomised pilot phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2\u00a0weekly with pegfilgrastim (accelerated) vs 3\u00a0weekly (standard) for women with early breast cancer. Br J Cancer 100:305\u2013310","journal-title":"Br J Cancer"},{"key":"3202_CR21","doi-asserted-by":"crossref","unstructured":"Burnell M, Shepherd K, Gelmon K, Bramwell V, Walley B, et al (2012) A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of the final relapse free survival analysis. Cancer Res 72 [24 Suppl 3, abstr P1-13-01]","DOI":"10.1158\/0008-5472.SABCS12-P1-13-01"},{"key":"3202_CR22","doi-asserted-by":"crossref","unstructured":"Budd GT, Barlow WE, Moore HCF, Hobday TJ, Stewart JA, et al (2013) Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. J Clin Oncol 31 (suppl; abstr CRA1008)","DOI":"10.1200\/jco.2013.31.18_suppl.cra1008"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-3202-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-014-3202-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-014-3202-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T08:32:28Z","timestamp":1566030748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-014-3202-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,16]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3202"],"URL":"https:\/\/doi.org\/10.1007\/s10549-014-3202-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,16]]}}}